Vision

Introduction

Despite major efforts, cancer has remained one of the major health problems and is the second most common cause of death in nearly all developed countries. There is no single solution to battle this complex disease and there is a permanent need for novel strategies to cure and treat different forms of cancer.

At Kiadis Pharma, we focus our expertise on the development of novel products targeting complications and limitations in hematopoietic stem cell transplantations (HSCT) as a treatment for end stage blood cancer patients (i.e. leukemia’s, lymphoma’s and multiple myeloma).